Clin2
NCT07249554Possibly a fitNot yet recruiting

Combination therapy for alcohol use disorder

Alcohol Use Disorder

Treatments studied

Part of Mental health clinical trials.

This trial tests two medicines — semaglutide and naltrexone — taken together to help reduce alcohol cravings and drinking. It aims to see if this combination is more effective than standard treatment for alcohol use disorder.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
45 people
Ages
21 years to 65 years
Study type
Interventional

Who can take part

  • You are between 21 and 65 years old
  • You have been diagnosed with alcohol use disorder
  • You have been at Ashley Addiction Treatment center for at least one week before starting
  • You are not pregnant, breastfeeding, or planning to become pregnant during the study
  • You do not have a history of pancreatitis, diabetes, or serious liver, kidney, or gallbladder disease
  • You are not currently taking certain diabetes drugs or opioid medications

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05028062Recruiting· Phase 4
Naltrexone injections for people who want to cut alcohol drinking

This Phase 4 study tests whether naltrexone injections can help people with alcohol use disorder (AUD) reduce or stop heavy drinking. You may get two injections over 8 weeks, and you can join if you meet specific drinking pattern and eligibility rules.

Philadelphia, Pennsylvania
NCT07223983Recruiting· Phase 1
Semaglutide for alcohol use disorder after weight loss surgery

This trial tests if a once-weekly diabetes medication (semaglutide) can help people with alcohol use disorder who have had gastric bypass or sleeve gastrectomy in the past 7 years. It may reduce alcohol cravings or drinking.

New Haven, Connecticut
NCT06546384Not yet recruiting
Semaglutide for alcohol use and liver health in obesity and fatty liver

This study tests if semaglutide (a GLP-1 RA medicine) can reduce alcohol consumption and improve liver fat and metabolism in people with obesity and fatty liver disease who drink above certain levels.

Bern
NCT07218354Recruiting· Phase 3
Medication for reducing alcohol use in veterans

This study tests whether a medication (semaglutide) can help veterans reduce or stop drinking alcohol. It is for veterans who drink heavily and have alcohol use disorder, and who are interested in cutting down.

Long Beach, California
NCT07520292Recruiting· Phase 1
Testing NTX-2001 to reduce drinking in alcohol use disorder

This study tests whether a new medication called NTX-2001 can help people with alcohol use disorder drink less. Researchers will measure how the drug affects alcohol consumption and safety in adults aged 21–60.

New Haven, Connecticut
NCT05988632Recruiting· Phase 1/Phase 2
Insulin nasal spray for alcohol use disorder

This trial tests whether a nasal spray with insulin can help people with alcohol use disorder. It may affect how the brain responds to alcohol and reduce drinking.

Providence, Rhode Island

Hear when a new Alcohol Use Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.